首页> 外文期刊>Chronic respiratory disease. >Diagnosis of chronic obstructive pulmonary disease earlier than current Global Initiative for Obstructive Lung Disease guidelines using a feasible spirometry parameter (maximal-mid expiratory flow/forced vital capacity)
【24h】

Diagnosis of chronic obstructive pulmonary disease earlier than current Global Initiative for Obstructive Lung Disease guidelines using a feasible spirometry parameter (maximal-mid expiratory flow/forced vital capacity)

机译:使用可行的肺活量测定参数(最大中度呼气流量/强制肺活量),比当前的《全球阻塞性肺疾病倡议》指南更早地诊断慢性阻塞性肺疾病

获取原文
获取原文并翻译 | 示例
           

摘要

Some patients suffer from clinical symptoms of chronic obstructive pulmonary disease (COPD) but their pulmonary function tests are in the normal range (at risk group). The objective of this study was to discover a practical test to distinguish these patients from non-COPD subjects. A total of 77 subjects including 40 COPD patients, 37 subjects at risk for developing COPD, and 32 control subjects were entered in this study. The accuracy of maximal-mid expiratory flow (MMEF)/forced vital capacity (FVC) for the diagnosis of COPD in at risk patients and its capability to differentiate from early COPD and normal patients were evaluated. Body plethysmography was used for measurement of lung volume as the Global Initiative for Obstructive Lung Disease standard. MMEF/FVC in the at risk group of COPD (0.73 ± 0.19) was significantly lower than the normal control group (0.9 ± 0.24, respectively), and also, it was significantly higher than the COPD group (0.31 ± 0.17). There was significant correlation between the MMEF/FVC and amount of smoking measured by pack year (r2 = 0.112, p = 0.005) and stages of COPD (Spearman's ρ = 0.82, p = 0.0001). Early stage COPD (smoker subjects without spirometry derangement) can be diagnosed by MMEF/FVC. Using this tool we may be able to detect this highly preventable disease at an earlier stage.
机译:一些患者患有慢性阻塞性肺疾病(COPD)的临床症状,但其肺功能检查处于正常范围(危险组)。这项研究的目的是发现一种实用的测试方法,以区分这些患者与非COPD患者。本研究共纳入77位受试者,其中包括40位COPD患者,37位有发展为COPD风险的受试者和32位对照受试者。评估了最大中度呼气流量(MMEF)/强迫肺活量(FVC)在高危患者中诊断COPD的能力以及其与早期COPD和正常患者的区分能力。人体体积描记术被用作全球阻塞性肺疾病倡议标准的肺量测量。 COPEF高危组的MMEF / FVC(0.73±0.19)显着低于正常对照组(分别为0.9±0.24),也显着高于COPD组(0.31±0.17)。 MMEF / FVC与按包装年份(r2 = 0.112,p = 0.005)和COPD分期(Spearmanρ= 0.82,p = 0.0001)测量的吸烟量之间存在显着相关性。 MMEF / FVC可诊断出早期COPD(无肺活量测定紊乱的吸烟者)。使用此工具,我们也许能够在早期阶段检测出这种高度可预防的疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号